Annual General Meeting Presentation 2017

November 17, 2017 Kerry Rowe

AGM Presentation 2017

Post navigation

New data independently confirms and extends laboratory findings and expands safety profile of ATH434
Alterity Therapeutics meeting with US FDA provides development pathway for ATH434
Alterity Therapeutics presents data on ATH434 to the American Academy of Neurology
Alterity receives a $4.8 million R&D Tax Incentive Refund
European Commission approves Orphan Designation for Alterity’s lead drug candidate

We exist to create an alternate future for people living with neurodegenerative diseases. An alternate, healthier life. We’re here to disrupt the trajectory the world has come to accept for people with these diseases.
Improving lives.

Pipeline
The Science
About us
Investors
News

Careers
Privacy Policy

Annual General Meeting Presentation 2017

Related Posts

Pre-clinical evidence demonstrates PBT434 as a potential treatment for MSA

Prana Provides Clinical Trials Update

Prana meeting with investors at world’s largest healthcare conference in San Francisco